Nucleome Therapeutics Ltd

Scientific Foundation

The overwhelming majority of genetic variants associated with common diseases lie outside the protein-coding regions of the genome. These non-coding regions, sometimes described as the "dark matter" of the genome, contain regulatory elements that control when, where, and how much genes are expressed. Because these elements can act over long distances and are highly cell-type specific, understanding how a disease-linked variant influences a particular gene has historically been extremely difficult.

Nucleome Therapeutics was founded to address this challenge directly. The company's science is rooted in the work of its academic founders, who developed high-resolution methods for mapping the three-dimensional folding of the genome inside the cell nucleus. By understanding how distant regulatory elements physically interact with gene promoters, the company aims to reveal the precise causal mechanisms linking genetic risk factors to disease biology. This approach allows the identification of drug targets that are supported by direct human genetic evidence, an attribute strongly associated with higher success rates in drug development.

What the Company Does

Nucleome Therapeutics operates as a target discovery and drug discovery company. Its central activity is translating human genetic association data into validated, actionable drug targets by resolving the regulatory relationships hidden within the non-coding genome. The company focuses on immune cells and immune-mediated diseases, where genetic evidence is particularly rich and where precise understanding of gene regulation in specific cell types can uncover new therapeutic opportunities.

The company's work broadly spans three connected areas:

• Mapping genome architecture at high resolution to determine which regulatory elements interact with which genes in disease-relevant cells.
• Interpreting disease-associated non-coding genetic variants to identify the causal genes and pathways underlying inflammatory and immune disorders.
• Advancing this insight into drug discovery programmes aimed at delivering precision medicines for patients whose disease is driven by these specific mechanisms.

Core Technology Platform

Nucleome's differentiation lies in an integrated platform that brings together experimental genomics and computational analysis. The key components include:

High-Resolution Genome Folding Technology

The company employs advanced chromosome conformation capture methods capable of mapping physical contacts between regulatory elements and gene promoters at fine resolution. This enables the company to see, at the level of individual cell types, how a genetic variant located far from any gene can nonetheless control that gene's activity. This spatial map of the genome is central to linking non-coding variation to its functional consequences.

Functional Genomics and Cellular Models

Nucleome combines its genome folding maps with functional assays in relevant primary immune cells. By working in disease-relevant cellular contexts, the company ensures that the regulatory interactions it identifies are biologically meaningful and directly connected to human disease processes rather than to generic or non-specific cell states.

Machine Learning and Data Integration

The company applies machine learning and computational biology to integrate large-scale genomic datasets, including genome architecture data, gene expression data, and human genetic association data. This computational layer allows Nucleome to prioritise variants, pinpoint causal genes, and generate testable hypotheses about disease mechanisms at scale. The interplay between experimental data and predictive modelling is a defining feature of the platform.

Products and Services

Nucleome Therapeutics is primarily a drug discovery organisation rather than a provider of catalogue products or contract services. Its outputs and offerings can be understood as follows:

Validated Drug Targets

A core product of Nucleome's platform is a pipeline of novel, genetically validated drug targets. By resolving which genes are causally responsible for disease risk encoded in the non-coding genome, the company generates targets that carry strong human genetic support. These targets form the basis of the company's own therapeutic programmes and represent significant value for partnering.

Precision Medicine Programmes

The company is developing therapeutic programmes focused on immune-mediated and inflammatory diseases. These programmes are built around the causal biology uncovered by the platform, with the goal of delivering precision medicines that target the specific mechanisms driving disease in defined patient populations.

Disease Mechanism Insights

Through its ability to interpret the functional consequences of non-coding genetic variants, Nucleome produces detailed insights into disease mechanisms. This understanding not only supports internal drug discovery but also underpins strategic collaborations with larger pharmaceutical partners seeking to expand their own target discovery capabilities.

Partnerships and Collaborations

Nucleome pursues collaborations with pharmaceutical and biotechnology organisations that wish to leverage its genome interpretation platform. Such partnerships typically involve applying the company's technology to identify and validate targets in areas of shared interest, combining Nucleome's genomic expertise with the development and commercialisation capabilities of larger partners.

Therapeutic Focus

The company concentrates on immune-mediated and inflammatory diseases. These conditions are strongly influenced by genetic variation in immune cells, and much of the associated genetic risk lies in the non-coding regions of the genome that Nucleome specialises in decoding. By focusing on this area, the company positions its technology where it can have the greatest impact, uncovering new biology in a domain characterised by significant unmet medical need and complex, multifactorial disease drivers.

Origins and Location

Nucleome Therapeutics is headquartered in Oxford, United Kingdom, benefiting from proximity to the University of Oxford and the wider Oxford life sciences ecosystem. The company emerged from world-leading academic research into genome biology and gene regulation, and it maintains close ties to the scientific community from which it originated. Its founding scientists are recognised authorities in the fields of chromatin biology, genome architecture, and functional genomics.

Strategic Position and Significance

Nucleome Therapeutics addresses one of the most important unsolved problems in modern drug discovery: how to convert the enormous volume of human genetic association data into concrete, actionable drug targets. While genome-wide association studies have identified thousands of disease-linked variants, the functional interpretation of these variants, especially those in non-coding regions, has lagged far behind. By providing a systematic means to bridge this gap, Nucleome offers a route to targets that are more likely to succeed in the clinic because they are grounded in human biology.

The company's integrated approach, uniting high-resolution experimental genomics with computational interpretation, distinguishes it from organisations that rely on genetics or functional data alone. This combination positions Nucleome as a contributor to the growing movement toward genetically validated, precision medicine in immunology and inflammation.

Summary

Nucleome Therapeutics Ltd is an Oxford-based biotechnology company dedicated to decoding the non-coding "dark matter" of the human genome. Through proprietary high-resolution genome folding technology, functional genomics in immune cells, and machine learning, the company links disease-associated genetic variation to its causal genes and mechanisms. Its principal outputs are genetically validated drug targets and precision medicine programmes focused on immune-mediated and inflammatory diseases, supported by partnerships that extend the reach of its genome interpretation platform. In doing so, Nucleome aims to unlock new therapeutic opportunities that are firmly rooted in human genetic evidence.